> Once, the gap between prescription drugs and over-the-counter sales was a wide No Man's Land where few products roamed. Now, the FDA may settle more medications in this country, known as behind-the-counter (BTC) sales, in part to improve access for the uninsured. Report [1]
> Hyperion Therapeutics [2] has made senior management appointments and closed up to $15 million in debt financing from Comerica Bank and Life Sciences Capital. Release [3]
> Hollis-Eden [4] has reported preclinical data for HE3235, a cancer treatment. Release [5]
> One more strike against diabetes drugs: Australia's regulators are warning that the class of drugs including Avandia and Actos may boost the risk of bone fractures in older women. Report [6]
> There has been a deluge of Gardasil/Cervarix news in the last few weeks as GSK and Merck fight for ascendancy in the multi-billion dollar market. Report [7]
And Finally... University of Cincinnati researchers believe identifying a genetic "fingerprint" could help predict which specific therapies will be most effective for patients with gastric cancer. Release [8]
Links:
[1] http://www.fiercepharma.com/story/fda-mulls-behind-counter-drug-sales/2007-10-04
[2] http://www.fiercebiotech.com/story/hyperion-garners-40m-second-vc-round/2007-09-05
[3] http://www.fiercebiotech.com/press-releases/press-release-hyperion-therapeutics-announces-senior-management-team-and-15m-financ-0
[4] http://www.fiercebiotech.com/story/emerging-drug-developer-hollis-eden/2007-08-31
[5] http://www.fiercebiotech.com/press-releases/press-release-hollis-eden-pharmaceuticals-presents-positive-results-novel-drug-candid
[6] http://www.fiercepharma.com/story/diabetes-drugs-linked-fracture-risk/2007-10-04
[7] http://www.fiercepharma.com/story/its-merck-v-glaxo-vaccine-battle/2007-10-04
[8] http://www.fiercebiotech.com/press-releases/press-release-identifying-genetic-fingerprint-may-predict-drug-effectiveness